## Abstract Sera of eight unselected adult patients with acute myelogenous leukemia obtained before and after chemotherapy were repeatedly tested for specific complement‐dependent cytotoxicity against autochthonous peripheral white blood cells from the acute leukemia stage and from the remission st
Demonstration of antibody-associated cellular cytotoxicity in patients with acute myelogenous leukemia before and after chemotherapy
✍ Scribed by R. Fäldt; J. Ankerst
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- French
- Weight
- 814 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
This study demonstrates that a cytotoxic serum reactivity not requiring the presence of complement appears in the sera of patients with acute myelogenous leukemia. The reaction is detected upon short‐term incubation of sera in vitro with autochthonous mononuclear white blood cells from peripheral venous blood of patients at the acute stage of the disease. This reactivity was demonstrated in 18/18 patients. Generally, the cytotoxicity was low in patients at the acute stage of the disease, but increased after chemotherapy and reached the highest level at the onset of clinical remission or just before. No cytotoxicity could be demonstrated against autochthonous remission white blood cells. The serum activity could be absorbed and eluted from protein A‐Sepharose CL‐4B and was recovered in the 7S‐fraction of the sera after gel filtration on Sephadex G‐200 and ion exchange chromatography. This indicates that the demonstrated cytotoxicity is due to immunoglobulins of IgG‐class. It is believed that Fc‐receptor‐bearing cells present in the target cell preparations function as effector cells. The reaction is designated antibody‐associated cellular cytotoxicity (AACC).
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA
## Abstract ## BACKGROUND The optimal antifungal prophylactic regimen for patients with acute myelogenous leukemia (AML) or high‐risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy has yet to be identified. A prospective historical control study evaluated the efficacy and safety